NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
17 07 2023
17 07 2023
Historique:
received:
30
12
2022
accepted:
09
06
2023
revised:
26
04
2023
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Natural Killer (NK) cells act as important regulators in the development and progression of hematological malignancies and their suppressor activity against Multiple Myeloma (MM) cells has been confirmed in many studies. Significant changes in the distribution of NK cell subsets and dysfunctions of NK cell effector activities were described in MM patients and correlated with disease staging. Thus, restoring or enhancing the functionality of these effectors for the treatment of MM represents a critical need. Neddylation is a post-translational modification that adds a ubiquitin-like molecule, NEDD8, to the substrate protein. One of the outcomes is the activation of the Cullin Ring Ligases (CRLs), a class of ubiquitin-ligases that controls the degradation of about 20% of proteasome-regulated proteins. Overactivation of CRLs has been described in cancer and can lead to tumor growth and progression. Thus, targeting neddylation represents an attractive approach for cancer treatment. Our group has recently described how pharmacologic inhibition of neddylation increases the expression of the NKG2D activating receptor ligands, MICA and MICB, in MM cells, making these cells more susceptible to NK cell degranulation and killing. Here, we extended our investigation to the direct role of neddylation on NK cell effector functions exerted against MM. We observed that inhibition of neddylation enhanced NK cell-mediated degranulation and killing against MM cells and improved Daratumumab/Elotuzumab-mediated response. Mechanistically, inhibition of neddylation increased the expression of Rac1 and RhoA GTPases in NK cells, critical mediators for an efficient degranulation at the immunological synapse of cytotoxic lymphocytes, and augmented the levels of F-actin and perforin polarization in NK cells contacting target cells. Moreover, inhibition of neddylation partially abrogated TGFβ-mediated repression of NK cell effector activity. This study describes the role of neddylation on NK cell effector functions and highlights the positive immunomodulatory effects achieved by the inhibition of this pathway in MM.
Identifiants
pubmed: 37460534
doi: 10.1038/s41419-023-05949-z
pii: 10.1038/s41419-023-05949-z
pmc: PMC10352239
doi:
Substances chimiques
NEDD8 Protein
0
Antineoplastic Agents
0
Proteins
0
Ligases
EC 6.-
NEDD8 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
438Informations de copyright
© 2023. The Author(s).
Références
Nat Immunol. 2005 Jun;6(6):600-7
pubmed: 15852008
Nat Rev Immunol. 2008 Sep;8(9):713-25
pubmed: 19172692
Clin Cancer Res. 2016 Jan 1;22(1):34-43
pubmed: 26561559
Nat Commun. 2022 May 31;13(1):3021
pubmed: 35641500
Immun Inflamm Dis. 2020 Dec;8(4):782-792
pubmed: 32749072
N Engl J Med. 2018 Nov 8;379(19):1811-1822
pubmed: 30403938
Adv Exp Med Biol. 2020;1217:297-315
pubmed: 31898235
Curr Pharm Des. 2013;19(18):3215-25
pubmed: 23151137
Leukemia. 2015 Jun;29(6):1441-4
pubmed: 25634684
Front Immunol. 2022 Jan 11;12:816499
pubmed: 35087536
Curr Cancer Drug Targets. 2011 Mar;11(3):347-56
pubmed: 21247385
Int J Mol Sci. 2021 Apr 24;22(9):
pubmed: 33923357
Front Immunol. 2019 Nov 15;10:2689
pubmed: 31803194
Cancer Res. 2021 Oct 1;81(19):5007-5020
pubmed: 34362797
Br J Haematol. 2002 Dec;119(3):660-4
pubmed: 12437641
Proc Natl Acad Sci U S A. 2014 May 6;111(18):6708-13
pubmed: 24760828
J Immunol. 2008 Sep 15;181(6):3784-92
pubmed: 18768831
Expert Opin Investig Drugs. 2012 Oct;21(10):1563-73
pubmed: 22799561
Curr Cancer Drug Targets. 2017;17(9):806-818
pubmed: 28201978
Mol Cell. 2013 Feb 7;49(3):499-510
pubmed: 23290524
Bone. 2011 Jan;48(1):129-34
pubmed: 20570621
Leukemia. 2021 Jan;35(1):156-168
pubmed: 32203139
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4120-5
pubmed: 12646700
Br J Haematol. 2015 May;169(4):534-43
pubmed: 25733005
Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1285-90
pubmed: 18202175
Immunol Rev. 2013 Nov;256(1):107-17
pubmed: 24117816
J Cell Sci. 2010 Dec 1;123(Pt 23):4011-8
pubmed: 21084561
Blood. 2021 Apr 15;137(15):2033-2045
pubmed: 33513601
Mol Cancer Ther. 2012 Apr;11(4):942-51
pubmed: 22246439
J Immunol. 2009 Oct 1;183(7):4385-94
pubmed: 19748980
Oncologist. 2020 Sep;25(9):e1406-e1413
pubmed: 32335971
Mol Cell. 2009 Sep 24;35(6):841-55
pubmed: 19782033
Immunity. 2006 May;24(5):575-90
pubmed: 16713975
Blood. 2005 Jan 1;105(1):251-8
pubmed: 15328155
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):974-9
pubmed: 11158580
PLoS Pathog. 2021 Sep 9;17(9):e1009936
pubmed: 34499701
Expert Rev Hematol. 2019 Jun;12(6):425-435
pubmed: 31070067
Neoplasia. 2006 Aug;8(8):677-88
pubmed: 16925950
Blood. 2010 Sep 2;116(9):1515-23
pubmed: 20525923
Cancer. 2019 Jul 15;125(14):2364-2382
pubmed: 30951198
Cancers (Basel). 2018 Nov 29;10(12):
pubmed: 30501078
Cancers (Basel). 2021 Jan 10;13(2):
pubmed: 33435153
J Immunol. 2013 Jun 15;190(12):6662-72
pubmed: 23686482
PLoS One. 2013 Oct 04;8(10):e75200
pubmed: 24124476
Cancer Res. 2015 Nov 15;75(22):4766-77
pubmed: 26438594
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):624-9
pubmed: 23267066
Dev Cell. 2018 Dec 3;47(5):592-607.e6
pubmed: 30513302
Cancer Treat Rev. 2018 Nov;70:255-264
pubmed: 30326421
J Exp Med. 2017 Apr 3;214(4):1203
pubmed: 28292823
Trends Immunol. 2010 Jun;31(6):220-7
pubmed: 20538542
Sci Immunol. 2022 Mar 18;7(69):eabi4613
pubmed: 35302863
Clin Cancer Res. 2016 Feb 15;22(4):847-57
pubmed: 26423795
Acta Pharm Sin B. 2020 May;10(5):746-765
pubmed: 32528826
J Immunol. 2015 Jul 15;195(2):736-48
pubmed: 26071561
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
Blood. 2010 May 6;115(18):3796-800
pubmed: 20203261
Neuro Oncol. 2010 Jan;12(1):7-13
pubmed: 20150362
Blood. 2010 Sep 30;116(13):2286-94
pubmed: 20460501
FEBS J. 2021 Jul;288(13):3884-3912
pubmed: 33025631
Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):e219-e240
pubmed: 29793653
J Clin Invest. 2015 May;125(5):2077-89
pubmed: 25893601
J Clin Med. 2020 Dec 30;10(1):
pubmed: 33396800
Cell. 2011 Oct 14;147(2):459-74
pubmed: 21963094
Biomed Res Int. 2015;2015:178698
pubmed: 26161387